Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Stacy Cline Amin spoke to Bloomberg Law for an article looking at how Robert Califf, in his return as commissioner of the Food and Drug Administration (FDA), will likely prioritize improving drug competition and boosting patient access to innovative treatments.

Califf’s Return as FDA Head Will Give Drug Competition a Boost

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Stacy Cline Amin spoke to Bloomberg Law for an article looking at how Robert Califf, in his return as commissioner of the Food and Drug Administration (FDA), will likely prioritize improving drug competition and boosting patient access to innovative treatments.According to Stacy, the increased attention to the FDA’s role in drug pricing marks a change from previous years.“One of the things that has been interesting in this administration is seeing FDA wade into discussions that it has traditionally tried very hard to not be involved in, like patent law discussions,” Stacy said. She added that the FDA has typically avoided discussions on drugmaker patent practices, such as filing patents for the sole purpose of weeding out competitors.Read the <a href="https://www.bloomberglaw.com/product/blaw/bloomberglawnews/bloomberg-law-news/X5QV5TM0000000?resource_id=70faab7602229332da2fd6ff37df68c5%3FisAlert%3Dtrue&udvType=Alert" target="_blank">full article</a> (subscription required).